Ultragenyx Pharmaceutical Inc. shares plunged 30% as UX143 trial raises efficacy doubts. Click for more on RARE and my ...

Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...

According to Google, “bioresonance” is a form of oscillation medicine, founded on the theory of quantum physics, that all matter is in motion, oscillating and vibrating. This motion is in the form of ...

Several outbreaks of canine parvovirus, also known as parvo, have been reported in Ontario over the last year.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced that the randomized, placebo-controlled Phase ...

About the Setrusumab Phase 3 Program Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 ...

RISE Integrated Mental Health in York, Maine, offers ketamine therapy for trauma and depression, attracting patients ...

Global Recognition Awards™ has honored Viceroy Bali with a 2025 Global Recognition Award for Bali’s Best Luxury Resort, ...